Pasireotide
Signifor Lar, Signifor (pasireotide) is a protein pharmaceutical. Pasireotide was first approved as Signifor Lar on 2012-04-24. It is used to treat cushing syndrome in the USA. It has been approved in Europe to treat acromegaly and pituitary acth hypersecretion. The pharmaceutical is active against somatostatin receptor type 3, somatostatin receptor type 1, somatostatin receptor type 2, and somatostatin receptor type 5. Signifor's patents are valid until 2028-05-23 (FDA).
| Trade Name | Signifor |
|---|---|
| Common Name | Pasireotide |
| Indication | acromegaly, cushing syndrome, pituitary acth hypersecretion |
| Drug Class | Peptides: inhibition of growth hormone release |
